Allena Pharmaceuticals Inc. (ALNA)
0.07
-0.00 (-3.71%)
Sep 07, 2022, 8:00 PM - Market open
-3.71% (1D)
| Bid | n/a |
| Market Cap | 0 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.62M |
| EPS (ttm) | -0.638 |
| PE Ratio (ttm) | -0.11755485893416928 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 252,311,606 |
| Avg. Volume (20D) | undefined |
| Open | 0.06 |
| Previous Close | 0.07 |
| Day's Range | 0.06 - 0.15 |
| 52-Week Range | undefined - undefined |
| Beta | 1.15 |
About ALNA
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newto...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 2, 2017
Employees 12
Stock Exchange NASDAQ
Ticker Symbol ALNA
Website https://www.allenapharma.com